- Home
- KF vs PROK Comparison
KF vs PROK Comparison
Compare KF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- PROK
- Stock Information
- Founded
- KF 1984
- PROK 2015
- Country
- KF United States
- PROK United States
- Employees
- KF N/A
- PROK N/A
- Industry
- KF Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KF Finance
- PROK Health Care
- Exchange
- KF Nasdaq
- PROK Nasdaq
- Market Cap
- KF 83.7M
- PROK 94.9M
- IPO Year
- KF N/A
- PROK N/A
- Fundamental
- Price
- KF $20.90
- PROK $0.70
- Analyst Decision
- KF
- PROK Buy
- Analyst Count
- KF 0
- PROK 4
- Target Price
- KF N/A
- PROK $5.00
- AVG Volume (30 Days)
- KF 18.4K
- PROK 1.2M
- Earning Date
- KF 01-01-0001
- PROK 05-16-2025
- Dividend Yield
- KF N/A
- PROK N/A
- EPS Growth
- KF N/A
- PROK N/A
- EPS
- KF N/A
- PROK N/A
- Revenue
- KF N/A
- PROK $76,000.00
- Revenue This Year
- KF N/A
- PROK N/A
- Revenue Next Year
- KF N/A
- PROK N/A
- P/E Ratio
- KF N/A
- PROK N/A
- Revenue Growth
- KF N/A
- PROK N/A
- 52 Week Low
- KF $18.30
- PROK $0.46
- 52 Week High
- KF $25.56
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- KF 57.20
- PROK 41.32
- Support Level
- KF $20.77
- PROK $0.62
- Resistance Level
- KF $21.48
- PROK $0.77
- Average True Range (ATR)
- KF 0.34
- PROK 0.13
- MACD
- KF 0.10
- PROK -0.01
- Stochastic Oscillator
- KF 62.09
- PROK 17.35
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.